(Q43041038)

English

Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection

scientific article published in January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Giuliano Ramadori

5

object named as

Giuliano Ramadori

1 reference

Europe PubMed Central

12 November 2017

3

object named as

Sabine Mihm

1 reference

Europe PubMed Central

12 November 2017

author name string

Volker Meier

1

1 reference

Europe PubMed Central

12 November 2017

Erik Bürger

2

1 reference

Europe PubMed Central

12 November 2017

Bernhard Saile

4

1 reference

Europe PubMed Central

12 November 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

12 November 2017

Journal of Medical Virology

1 reference

Europe PubMed Central

12 November 2017

69

1 reference

Europe PubMed Central

12 November 2017

50-58

1 reference

Europe PubMed Central

12 November 2017

1

1 reference

Europe PubMed Central

12 November 2017

Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Ribavirin's antiviral mechanism of action: lethal mutagenesis?

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Ribonucleic acid isolated by cesium chloride centrifugation

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

The role of immune responses in the pathogenesis of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

High inflammatory activity is associated with an increased amount of IFN-gamma transcripts in peripheral blood cells of patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Adverse effects and drug interactions of clinical importance with antiviral drugs

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Lymphocyte responses and cytokines

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Comparative production of IL-1 beta and IL-1 alpha by LPS-stimulated human monocytes: ELISAs measurement revisited

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

ELISA kits based on monoclonal antibodies do not measure total IL-1 beta synthesis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand

1 reference

https://api.crossref.org/works/10.1002%2FJMV.10264

21 January 2018

Identifiers

10.1002/JMV.10264

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43041038&oldid=1978322057"